MRC1 and cancer: We anticipate that the upcoming ACMG/AMP guidelines that include the CIMRA assay as a strong evidence type to classify VUS in all four MMR genes will not only significantly advance their classification worldwide, but also provide a paradigm for the translation of personalized cancer genetics into personalized healthcare.